ArticleInfection and drug resistance2024
Risk Factors for Development and Mortality of Bloodstream Infections Caused by Carbapenem-Resistant
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Analysis of clinical characteristics and whole-genome sequencing of carbapenem-resistant Acinetobacter baumannii isolates from pediatric patients in Guangxi, China.BMC microbiology · 2026Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Carbapenem-resistantFrontiers in medicine · 2026Article
- Prognostic Indicators of Carbapenem-ResistantHealth science reports · 2025Review
- The global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Early diagnosis and prognostic prediction of secondary bloodstream infections caused byFrontiers in cellular and infection microbiology · 2025Article
- Eravacycline Treatment for Carbapenem-ResistantInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bloodstream infections (BSIs) caused by Methods: This study aimed to analyze the clinical data and prognosis of 191 patients with AB-BSI hospitalized in Southern China from January 2017 to December 2023. Results: CRAB was diagnosed in 128 (67.0%) of the 191 patients with AB-BSI. Endotracheal intubation (OR = 23.957, 95% CI: 5.123-112.022, P < 0.001), carbapenem treatment (OR = 6.422, 95% CI: 1.554-26.542, P = 0.010) and ≥2 antimicrobial drugs therapy (OR = 6.131, 95% CI: 1.763-21.324, P = 0.004) prior to the onset of BSI were independent risk factors for the development of CRAB-BSI, as revealed by the binary logistic regression analysis. The overall mortality rate of patients with AB-BSI was 27.7%, while that of patients with CRAB was significantly higher than that of patients with carbapenem-sensitive Conclusion: Clinicians should closely monitor patients at high risk for CRAB-BSI, focusing on invasive procedure management and antimicrobial stewardship. Timely supportive care is crucial for CRAB-BSI patients at risk of septic shock to improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.